Cardioprotective effect and influence on NOS expression of Montelukast sodium in rats.
- Author:
Shan CHEN
1
;
Ge JIN
;
Jiang SHAN
;
Mei ZHANG
;
Qun MEN
;
Li XU
Author Information
- Publication Type:Journal Article
- MeSH: Acetates; pharmacology; Animals; Cardiotonic Agents; pharmacology; Female; Isoproterenol; Leukotriene Antagonists; pharmacology; Male; Myocardial Ischemia; chemically induced; enzymology; pathology; Myocardium; metabolism; pathology; Necrosis; Nitric Oxide Synthase; metabolism; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Quinolines; pharmacology; Rats; Rats, Sprague-Dawley
- From: Acta Pharmaceutica Sinica 2003;38(11):821-825
- CountryChina
- Language:Chinese
-
Abstract:
AIMTo determine the protective effect and influence on NOS expression of Montelukast sodium--a leukotriene antagonist on myocardial necrosis in rats.
METHODSMyocardial ischemia and necrosis were induced in rats by isoproterenol (2 mg.kg-1, s.c., qd for 2 d). Serum activity of LDH, CK, MDA, NO content in myocardium and scope of myocardial necrosis were measured. nNOS, iNOS and eNOS were investigated by immunohistochemical evaluation.
RESULTSDecreased serum level of LDH, CK, MDA and attenuated myocardial necrosis area were found in rats pretreated with Montelukast sodium 10 and 30 mg.kg-1. Montelukast sodium 30 mg.kg-1 also enhanced NO content in myocardium. Montelukast sodium activated the eNOS expression and reduced the iNOS expression.
CONCLUSIONMontelukast sodium is cardioprotective during myocardial injury in rats by halting the leukotrienes-induced inflammatory response and upregulating the eNOS expression as well as downregulating the iNOS expression. This may represent an approach to the treatment of myocardial ischemia with leukotriene antagonists.
